{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:32:41Z","timestamp":1792006361430,"version":"4.4.0"},"reference-count":56,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2018,12,2]],"date-time":"2018-12-02T00:00:00Z","timestamp":1543708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["2010JS3PMZ"],"award-info":[{"award-number":["2010JS3PMZ"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>Thromboxane (TX)-dependent platelet activation and lipid peroxidation, as reflected in vivo by the urinary excretion of 11-dehydro-TXB2 and 8-iso-prostaglandin (PG)F2\u03b1, play a key role in atherothrombosis in obesity and type 2 diabetes mellitus (T2DM) since the earlier stages. Thirty-five metformin-treated obese subjects with prediabetes or newly-diagnosed T2DM were randomized to the glucagon-like peptide receptor agonist (GLP-RA) liraglutide (1.8 mg\/day) or lifestyle counseling until achieving a comparable weight loss (\u22127% of initial body weight), to assess whether changes in subcutaneous (SAT) and visceral (VAT) adipose tissue distribution (MRI), insulin sensitivity (Matsuda Index) and beta-cell performance (multiple sampling OGTT beta-index), with either intervention, might affect TX-dependent platelet activation, lipid peroxidation and inflammation. At baseline, Ln-8-iso-PGF2\u03b1 (Beta = 0.31, p = 0.0088), glycosylated hemoglobin (HbA1c) (Beta = 2.64, p = 0.0011) Ln-TNF-\u03b1 (Beta = 0.58, p = 0.0075) and SAT (Beta = 0.14, p = 0.044) were significant independent predictors of 11-dehydro-TXB2. After achievement of the weight loss target, a comparable reduction in U-11-dehydro-TXB2 (between-group p = 0.679) and 8-iso-PGF-2\u03b1 (p = 0.985) was observed in both arms in parallel with a comparable improvement in glycemic control, insulin sensitivity, SAT, high-sensitivity C-reactive protein (hs-CRP). In obese patients with initial impairment of glucose metabolism, the extent of platelet activation is related to systemic inflammation, isoprostane formation and degree of glycemic control and abdominal SAT. Successful weight loss, achieved with either lifestyle changes or an incretin-based therapy, is associated with a significant reduction in lipid peroxidation and platelet activation.<\/jats:p>","DOI":"10.3390\/nu10121872","type":"journal-article","created":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T06:02:09Z","timestamp":1543816929000},"page":"1872","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Thromboxane-Dependent Platelet Activation in Obese Subjects with Prediabetes or Early Type 2 Diabetes: Effects of Liraglutide- or Lifestyle Changes-Induced Weight Loss"],"prefix":"10.3390","volume":"10","author":[{"given":"Paola","family":"Simeone","sequence":"first","affiliation":[{"name":"Department of Medicine and Aging and Center of Aging Science and Translational Medicine (CESI-Met), University of Chieti, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Liani","sequence":"additional","affiliation":[{"name":"Department of Medicine and Aging and Center of Aging Science and Translational Medicine (CESI-Met), University of Chieti, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romina","family":"Tripaldi","sequence":"additional","affiliation":[{"name":"Department of Medicine and Aging and Center of Aging Science and Translational Medicine (CESI-Met), University of Chieti, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto","family":"Di Castelnuovo","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Prevention, IRCCS NEUROMED, Via dell\u2019Elettronica, 86077 Pozzilli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Guagnano","sequence":"additional","affiliation":[{"name":"Department of Medicine and Aging and Center of Aging Science and Translational Medicine (CESI-Met), University of Chieti, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Tartaro","sequence":"additional","affiliation":[{"name":"Department of Neuroscience &amp; Imaging, University of Chieti, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo C.","family":"Bonadonna","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy"},{"name":"Division of Endocrinology and Metabolic Diseases, Azienda Ospedaliera Universitaria of Parma, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Federico","sequence":"additional","affiliation":[{"name":"Clinical Pathology, Chieti Hospital, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cipollone","sequence":"additional","affiliation":[{"name":"Department of Medicine and Aging and Center of Aging Science and Translational Medicine (CESI-Met), University of Chieti, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostino","family":"Consoli","sequence":"additional","affiliation":[{"name":"Department of Medicine and Aging and Center of Aging Science and Translational Medicine (CESI-Met), University of Chieti, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Santilli","sequence":"additional","affiliation":[{"name":"Department of Medicine and Aging and Center of Aging Science and Translational Medicine (CESI-Met), University of Chieti, 66100 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,12,2]]},"reference":[{"key":"ref_1","first-page":"77","article-title":"Intra-abdominal obesity: An untreated risk factor for Type 2 diabetes and cardiovascular disease","volume":"29","year":"2006","journal-title":"J. Endocrinol. Invest."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1056\/NEJM199006213222503","article-title":"Thromboxane biosynthesis and platelet function in type II diabetes mellitus","volume":"322","author":"Catalano","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jacc.2005.03.079","article-title":"Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus","volume":"47","author":"Santilli","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra071014","article-title":"Platelet activation and atherothrombosis","volume":"357","author":"Patrono","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.288.16.2008","article-title":"Platelet activation in obese women: Role of inflammation and oxidant stress","volume":"288","author":"Guagnano","year":"2002","journal-title":"JAMA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/j.1538-7836.2010.03742.x","article-title":"Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus","volume":"8","author":"Santilli","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"UK Prospective Diabetes Study (UKPDS) Group (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 352, 837\u2013853.","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N. Engl, J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N. Engl, J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S2213-8587(16)00082-6","article-title":"Phenotypes of prediabetes and stratification of cardiometabolic risk","volume":"4","author":"Stefan","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"672658","DOI":"10.1155\/2012\/672658","article-title":"Effects of glucagon-like peptide-1 receptor agonists on body weight: A meta-analysis","volume":"2012","author":"Monami","year":"2012","journal-title":"Exp. Diabetes Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3109\/00365529609009147","article-title":"Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day","volume":"31","author":"Orskov","year":"1996","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.2337\/db15-1141","article-title":"Glucagon-Like Peptide 1 Receptor Activation Attenuates Platelet Aggregation and Thrombosis","volume":"65","author":"Reheman","year":"2016","journal-title":"Diabetes"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1160\/TH16-07-0586","article-title":"Glucagon-like peptide 1-related peptides increase nitric oxide effects to reduce platelet activation","volume":"117","author":"Barale","year":"2017","journal-title":"Thromb. Haemost."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.2337\/dc17-0589","article-title":"Effects of Liraglutide on weight loss, fat distribution and beta-cell function in obese subjects with prediabetes or early type 2 diabetes mellitus","volume":"40","author":"Santilli","year":"2017","journal-title":"Diabetes Care"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2015). Classification and diagnosis of diabetes. Diabetes Care, 38, S8\u2013S16.","DOI":"10.2337\/dc15-S005"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jacc.2006.08.040","article-title":"Insulin resistance as a determinant of platelet activation in obese women","volume":"48","author":"Basili","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1152\/jappl.1992.72.2.787","article-title":"Quantification of adipose tissue by MRI: Relationship with anthropometric variables","volume":"72","author":"Ross","year":"1992","journal-title":"J. Appl. Physiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1046\/j.1365-2362.2001.00827.x","article-title":"Assessment of beta-cell function during the ora glucose tolerance test by a minimal model of insulin secretion","volume":"31","author":"Cretti","year":"2001","journal-title":"Eur. J. Clin. Invest."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.2337\/diacare.22.9.1462","article-title":"Insulin sensitivity indices obtained from oral glucose tolerance testing: Comparison with the euglycemic insulin clamp","volume":"22","author":"Matsuda","year":"1999","journal-title":"Diabetes Care"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"763","DOI":"10.5858\/1999-123-0763-EOAFAH","article-title":"Evaluation of a fully automated high-performance liquid chromatography assay for hemoglobin A1c","volume":"123","author":"Khuu","year":"1999","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jpeds.2014.01.052","article-title":"Insulin-like growth factor-I and -II levels are associated with the progression of nonalcoholic fatty liver disease in obese children","volume":"165","author":"Cianfarani","year":"2014","journal-title":"J. Pediatr."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1161\/01.CIR.85.5.1792","article-title":"Increased thromboxane biosynthesis in type IIa hypercholesterolemia","volume":"85","author":"Averna","year":"1992","journal-title":"Circulation"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0022-3565(25)12087-9","article-title":"Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man","volume":"275","author":"Wang","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2337\/diabetes.54.6.1615","article-title":"The Pathobiology of Diabetic Complications. A Unifying Mechanism","volume":"54","author":"Brownlee","year":"2005","journal-title":"Diabetes"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"EMPAREG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2337\/dc16-2736","article-title":"Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?","volume":"40","author":"DeFronzo","year":"2017","journal-title":"Diabetes Care"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2337\/db09-9028","article-title":"From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus","volume":"58","author":"Defronzo","year":"2009","journal-title":"Diabetes"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S2213-8587(13)70175-X","article-title":"Definition of intervention points in prediabetes","volume":"2","author":"Ferrannini","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2337\/dc08-1264","article-title":"Fasting versus postload plasma glucose concentration and the risk for future type 2 diabetes: Results from the Botnia Study","volume":"32","author":"Lyssenko","year":"2009","journal-title":"Diabetes Care"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S2213-8587(13)70008-1","article-title":"Trajectories of cardiometabolic risk factors before diagnosis of three subtypes of type 2 diabetes: A post-hoc analysis of the longitudinal Whitehall II cohort study","volume":"1","author":"Faerch","year":"2013","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s00125-010-1896-4","article-title":"Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: What is up, what is down?","volume":"54","author":"Nauck","year":"2011","journal-title":"Diabetologia"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1007\/s00125-016-4036-y","article-title":"LIGHT\/TNFSF14 is increased in patients with type 2 diabetes mellitus and promotes islet cell dysfunction and endothelial cell inflammation in vitro","volume":"59","author":"Halvorsen","year":"2016","journal-title":"Diabetologia"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/978-3-642-29423-5_11","article-title":"Thromboxane receptors antagonists and\/or synthase inhibitors","volume":"210","author":"Santilli","year":"2012","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1259\/bjr\/38447238","article-title":"The clinical importance of visceral adiposity: A critical review of methods for visceral adipose tissue analysis","volume":"85","author":"Shuster","year":"2012","journal-title":"Br. J. Radiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.numecd.2014.04.017","article-title":"Pro- and anti-inflammatory cytokine gene expression in subcutaneous and visceral fat in severe obesity","volume":"24","author":"Spoto","year":"2014","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000443691","article-title":"Relations of Visceral and Abdominal Subcutaneous Adipose Tissue, Body Mass Index, and Waist Circumference to Serum Concentrations of Parameters of Chronic Inflammation","volume":"9","author":"Schlecht","year":"2016","journal-title":"Obes. Facts"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1161\/CIRCULATIONAHA.106.675355","article-title":"Abdominal visceral and subcutaneous adipose tissue compartments: Association with metabolic risk factors in the Framingham Heart Study","volume":"116","author":"Fox","year":"2007","journal-title":"Circulation"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1161\/CIRCULATIONAHA.114.015000","article-title":"Association between visceral and subcutaneous adipose depots and incident cardiovascular disease risk factors","volume":"132","author":"Abraham","year":"2015","journal-title":"Circulation"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.jacc.2016.06.067","article-title":"Association of Changes in Abdominal Fat Quantity and Quality With Incident Cardiovascular Disease Risk Factors","volume":"68","author":"Lee","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_47","first-page":"4196","article-title":"Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo","volume":"82","author":"Goodrick","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/978-1-61779-307-3_17","article-title":"Culture of megakaryocytes and platelets from subcutaneous adipose tissue and a preadipocyte cell line","volume":"788","author":"Matsubara","year":"2012","journal-title":"Methods. Mol. Biol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"99","DOI":"10.4093\/dmj.2016.40.2.99","article-title":"An Update on the Effect of Incretin-Based Therapies on \u03b2-Cell Function and Mass","volume":"40","author":"Chon","year":"2016","journal-title":"Diabetes Metab. J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.2337\/dc14-0893","article-title":"Liraglutide and the preservation of pancreatic \u03b2-cell function in early type 2 diabetes: The LIBRA trial","volume":"37","author":"Retnakaran","year":"2014","journal-title":"Diabetes Care"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2337\/dbi16-0014","article-title":"Glucagon-Like Peptide 1 Receptor Activation and Platelet Function: Beyond Glycemic Control","volume":"65","author":"Jia","year":"2016","journal-title":"Diabetes"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Lattanzio, S., Santilli, F., Liani, R., Vazzana, N., Ueland, T., Di Fulvio, P., Formoso, G., Consoli, A., Aukrust, P., and Dav\u00ec, G. (2014). Circulating dickkopf-1 in diabetes mellitus: Association with platelet activation and effects of improved metabolic control and low-dose aspirin. J. Am. Heart Assoc., 3.","DOI":"10.1161\/JAHA.114.001000"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1160\/TH16-06-0471","article-title":"Increased circulating resistin is associated with insulin resistance, oxidative stress and platelet activation in type 2 diabetes mellitus","volume":"116","author":"Santilli","year":"2016","journal-title":"Thromb. Haemost."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.arr.2018.09.004","article-title":"Significance of urinary 11-dehydro-thromboxane b2 in age-related diseases: Focus on atherothrombosis","volume":"48","author":"Simeone","year":"2018","journal-title":"Ageing Res. Rev."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2018). Standards of Medical Care in Diabetes\u20142018. Diabetes Care, 41, S4\u2013S6.","DOI":"10.2337\/dc18-Srev01"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s40262-015-0343-6","article-title":"Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics","volume":"55","author":"Jacobsen","year":"2016","journal-title":"Clin. Pharmacokinet."}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/10\/12\/1872\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T08:22:59Z","timestamp":1775290979000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/10\/12\/1872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,2]]},"references-count":56,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["nu10121872"],"URL":"https:\/\/doi.org\/10.3390\/nu10121872","relation":{},"ISSN":["2072-6643"],"issn-type":[{"value":"2072-6643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,2]]}}}